Inflammatory breast cancer: A complex disease

ONCOLOGY

Volumn 22, Issue 14, 2008, Pages 1561-1566

  Dawood, Shaheenah ^a   Cristofanilli, Massimo ^b  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC GUANINE NUCLEOTIDE BINDING PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; WNT INDUCIBLE SIGNALING PATHWAY PROTEIN 3;

ADJUVANT THERAPY; BREAST CANCER; BREAST SURGERY; CANCER INCIDENCE; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; INFLAMMATORY BREAST CANCER; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

EID: 59349100037     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Lee BJ, Tannenbaum EN: Inflammatory carcinoma of the breast. Surg Gynecol Obstet 39:580-595, 1924.
2. Hance KW, Anderson WF, Devesa SS, et al: Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 97:966-975, 2005.
3. Houchens NW, Merajver SD: Molecular determinants of the inflammatory breast cancer phenotype. Oncology (Williston Park) 22:1556-1561, 2008.
4. Low J, Berman A, Steinberg S, et al: Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 22:4065-4074, 2004.
5. Ueno NT, Buzdar AU, Singletary SE, et al: Combined modality treatment of inflammatory breast carcinoma: Twenty years of experience at M.D. Anderson Center. Cancer Chemother Pharmacol 40:321-329, 1997.
6. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999.
7. Dawood S, Broglio K, Gong Y, et al, for the Inflammatory Breast Cancer Research Group: Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112:1905-1911, 2008.
8. Dawood S, Gonzalez-Angulo AM, Broglio K, et al: HER-2 positive inflammatory breast cancer: High pathological response rate with trastuzumab-based neoadjuvant therapy (abstract 4060). Breast Cancer Res Treat 106(suppl 1):2007.
9. Chu KC, Lamar CA, Freeman HP: Racial disparities in breast carcinoma survival rates: Separating factors that affect diagnosis from factors that affect treatment. Cancer 97:2853-2860, 2003.
10. Chlebowski RT, Chen Z, Anderson GL, et al: Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439-448, 2005.
11. Dawood SS, Broglio K, Shu-Wan Kau S, et al: Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes (abstract 87). Presented at the 2008 Breast Cancer Symposium; Washington, DC; September 5-7, 2008.
12. Dean-Colomb W, Yan K, Liedtke C, et al: Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women different (abstract 22014)? J Clin Oncol 26(15S):750s, 2008.